These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29480034)

  • 1. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia.
    Kavanagh S; Nee A; Lipton JH
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):51-62. PubMed ID: 29480034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to Consider Allogeneic Transplantation in CML.
    Radich J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S93-5. PubMed ID: 27521333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on emerging treatments for chronic myeloid leukemia.
    Fava C; Morotti A; Dogliotti I; Saglio G; Rege-Cambrin G
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):183-96. PubMed ID: 25826695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcr-Abl tyrosine kinase inhibitors: a patent review.
    Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
    Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
    Innes AJ; Apperley JF
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
    DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
    Luu MH; Press RD
    Expert Rev Mol Diagn; 2013 Sep; 13(7):749-62. PubMed ID: 24063401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Molica M; Alimena G
    Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.
    Gratwohl A; Baldomero H; Passweg J
    Ann Hematol; 2015 Apr; 94 Suppl 2():S177-86. PubMed ID: 25814084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era.
    Pasquini MC
    Hematology; 2012 Apr; 17 Suppl 1():S79-82. PubMed ID: 22507787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
    Copland M; Jørgensen HG; Holyoake TL
    Hematology; 2005 Oct; 10(5):349-59. PubMed ID: 16203604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.